HPV Vaccination & Cervical Screening Pathway

Cervical Cancer Prevention (NTAGI, FOGSI & WHO Guidelines) · v1.3
How to use this tool: Enter the age, sex, and the vaccination and screening history. The tool returns eligibility for HPV vaccination, the dose schedule, and the cervical screening due, following NTAGI and FOGSI guidance alongside global standards.
Vaccination does not replace screening, and a vaccinated woman is screened on the same schedule as anyone else. Current vaccines cover the types responsible for the large majority of cervical cancers but not all of them, and a woman vaccinated after exposure gains less. For screening intervals, an abnormal Pap or VIA result, CIN management or post-treatment surveillance, use the Cervical Screening and Abnormal Pap Management pathway.

Patient Demographics & History

Immunological Status

Ensure accurate selection, as immune compromise fundamentally alters the required vaccine dosing schedule regardless of age.

Academic Pearls & Pathophysiology

1. Pathophysiology: Why 2 Doses vs. 3 Doses?

The immune system's response to the HPV Virus-Like Particles (VLPs) is highly age-dependent. In early adolescence (ages 9–14), the naive immune system generates a strong B-cell memory response. Clinical trials proved that two doses in a 10-year-old produce significantly higher antibody titres than three doses in a 20-year-old. Once a patient reaches 15 years of age (or if they are immunocompromised), their immune geometry requires the traditional 3-dose prime-boost-boost schedule (0, 1-2, 6 months) to ensure durable immunity.

2. Clinical Caution: The "Already Active" Fallacy

Practice Advisory: A major barrier in India is withholding the vaccine from women who are already sexually active or who have an abnormal Pap smear, assuming it is "too late." This is clinically incorrect. The vaccine covers multiple oncogenic strains (e.g., 16, 18, 31, 33, 45, 52, 58). Exposure to one strain does NOT mean the patient is infected with all strains. Vaccination remains highly protective against the strains they have not yet encountered.

3. Clinical Caution: Screening Abandonment

Safety Alert: Vaccination is NOT a substitute for screening. The nonavalent vaccine covers strains responsible for ~90% of cervical cancers, meaning 10% of oncogenic strains remain uncovered. Fully vaccinated women must continue routine FOGSI/WHO-directed cervical screening (Pap smear or HPV DNA testing) according to age-based algorithms.

4. Illness Scripts: HPV Vaccines in India

Vaccine Type Strains Covered Clinical Utility
Bivalent (Cervarix) 16, 18 Protects against ~70% of cervical cancers. Does not protect against anogenital warts.
Quadrivalent (Gardasil / Cervavac) 16, 18, 6, 11 Protects against cervical cancer AND anogenital warts (strains 6, 11). Cervavac is the highly cost-effective indigenous Indian vaccine.
Nonavalent (Gardasil-9) 16, 18, 6, 11, 31, 33, 45, 52, 58 Broadest coverage. Protects against ~90% of cervical cancers and anogenital warts.

5. The WHO "90-70-90" Global Strategy

The WHO mandate to eliminate cervical cancer by 2030 rests on three pillars:

  • 90% of girls fully vaccinated with HPV vaccine by age 15.
  • 70% of women screened with a high-performance test by 35 years of age, and again by 45.
  • 90% of women identified with cervical disease receive treatment.
Abbreviations: CIN (Cervical Intraepithelial Neoplasia) · DNA (Deoxyribonucleic Acid) · FOGSI (Federation of Obstetric and Gynaecological Societies of India) · HIV (Human Immunodeficiency Virus) · HPV (Human Papillomavirus) · NTAGI (National Technical Advisory Group on Immunisation) · Pap (Papanicolaou Smear) · VIA (Visual Inspection with Acetic Acid) · VLP (Virus-Like Particle) · WHO (World Health Organization)
Algorithm References & Evidence Base
  1. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022;97(50):645-672.
  2. Meisner B, et al. FOGSI Good Clinical Practice Recommendations for Cervical Cancer Screening. 2023 Updates.
  3. National Technical Advisory Group on Immunisation (NTAGI) 17th Meeting Recommendations (2022): HPV vaccine inclusion in the Universal Immunisation Programme (UIP).
  4. Sankaranarayanan R, et al. HPV Vaccination and Screening: IARC India Trial. Lancet Oncol. 2022.
How to Cite This Tool

AMA Style:
Umakanth S. HPV Vaccination & Cervical Screening Pathway. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. HPV Vaccination & Cervical Screening Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Disclaimer and scope
Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was designed and developed by Dr. Shashikiran Umakanth using the available evidence base. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Immunisation & ProphylaxisPathway
Specialties Internal Medicine, Infectious Diseases, Obstetrics & Gynaecology
Written and maintained by Dr Shashikiran Umakanth.
Last revised: 29 July 2026
Related Clinical Tools
Cervical Screening & PapAdult Immunisation GuidePaediatric Immunisation Scheduler
Further Reading on MEDiscuss
Doctor, are vaccines really safe?A worked answer to the safety objection, for the consultation not the poster
Back to All Medical Calculators & Pathways